Hippocratic AI expanded into the life sciences sector through the acquisition of Grove AI, adding agentic AI capabilities for pharmaceutical research, development, and clinical trial operations. Alongside the acquisition, the company appointed a president of life sciences, formed a life sciences executive advisory council, and partnered with Boston Consulting Group to guide strategy and execution in biopharma and medtech environments.
The move builds on Hippocratic AI’s strong foundation in healthcare, where it has reached unicorn status with a $3.5 billion valuation and attracted investment from multiple U.S. health systems. By combining its safety-focused, patient-facing AI platform with life sciences–specific operational and research capabilities, the company is extending its role across the healthcare continuum, from care delivery and administration to clinical development and trials.